[Correspondence] Is it time to convert the frequency of radiotherapy in small-cell lung cancer? – Authors' reply

We thank Timur Mitin, Chukwuka Eze, and Haiyan Zeng and their colleagues for their interest and comments about the CONVERT trial.1 Mitin and colleagues raise the point that oncologists will consider the result of the trial to be equivalent in terms of whether to provide radiotherapy once-daily or twice-daily. CONVERT was designed to show superiority of once-daily radiotherapy and not powered for equivalence to twice-daily radiotherapy. Furthermore, compliance was better with twice-daily radiotherapy and more patients in this group received the full radiotherapy dose (98% for twice-daily vs 83% for once-daily, p<0·0001) and their planned overall treatment time (63% vs 48%, p=0·0004).

http://ift.tt/2fAtzKg